Article
EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib.
Journal of cancer research and clinical oncology - 1 Jun 2009
Xu Jian Ming, Han Yu, Duan Hai Qing, Gao E Mei, Zhang Yang, Liu Xiao Qing, Zhang Jing Sheng, Toschi Luca, Galetta Domenico, Azzariti Amalia, Paradiso Angelo
Abstract excerpt
BACKGROUND: To assess the role of various epidermal growth factor receptor (EGFR) mutations and HER2/3 protein expression as predictive markers of responsiveness to gefitinib therapy in Chinese patients with advanced non-small cell lung cancer (NSCLC). METHODS: A total of 106 Chinese NSCLC patien...
Topics
- Adult
- Aged
- Antineoplastic Agents
- Carcinoma, Non-Small-Cell Lung
- China
- DNA Mutational Analysis
- ErbB Receptors
- Female
- Gefitinib
- Humans
- Immunohistochemistry
- Kaplan-Meier Estimate
- Lung
- Lung Neoplasms
